Inhibikase Therapeutics, Inc. develops clinical-stage protein kinase inhibitor therapeutics for cardiopulmonary disease, with IKT-001, an oral prodrug of imatinib mesylate, as its lead program for pulmonary arterial hypertension. Company news centers on the IMPROVE-PAH clinical program, FDA interactions, clinical-development milestones, and PAH biology involving Abelson tyrosine kinase, platelet-derived growth factor receptors and c-KIT.
Recurring updates also cover operating results, development spending, equity compensation under Nasdaq rules, common-stock and warrant financing activity, and leadership or commercial-planning changes tied to the PAH program.
Inhibikase Therapeutics (Nasdaq: IKT) announced that Dr. Milton Werner, CEO, will present at the Grand Challenges in Parkinson's Disease Conference on September 28-29, 2022, in Grand Rapids, Michigan. The presentation focuses on IkT-148009, a potential disease-modifying therapy for Parkinson's disease, detailing outcomes from multiple pre-clinical studies. The session will occur at 3:00 PM EDT on September 28, highlighting the therapy's impact on multi-organ repair. Inhibikase is dedicated to developing treatments for neurodegenerative disorders related to Parkinson's disease.
Inhibikase Therapeutics reported positive results for its investigational drug IkT-148009, demonstrating high systemic exposure and good CNS penetration in older adults and Parkinson's patients, with no significant adverse events. The company is actively enrolling patients in the Phase 2a '201' clinical trial aimed at treating untreated Parkinson's disease. The data, presented at the International Congress of Parkinson's Disease and Movement Disorders, supports IkT-148009's safety profile and its potential to protect neurons and improve quality of life for patients.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its participation at the International Congress of Parkinson's Disease and Movement Disorders in Madrid, Spain, from September 15-18, 2022. CEO Milton Werner, Ph.D., will present the abstract titled "IkT-148009 as a potential disease-modifying therapy in PD" during the GPT 6 session on September 16, 2022, from 1:00 – 3:00 p.m. CEST. Inhibikase focuses on developing therapies for Parkinson's disease and related disorders, with their lead program targeting the Abelson Tyrosine Kinase pathway to potentially modify the disease's course.
Inhibikase Therapeutics (IKT) announced the appointment of Gisele Dion to its Board of Directors, effective September 1, 2022, as she succeeds retiring member Elizabeth O'Farrell. Dion, who has extensive experience in public companies, will chair the Audit Committee and serve on the Compensation Committee. Milton H. Werner, CEO, expressed optimism about Dion's expertise in finance and mergers, which can enhance Inhibikase's efforts in developing therapeutics for Parkinson's and related diseases. Her previous roles include senior positions at Takeda Pharmaceuticals and Shire Pharmaceuticals.
Inhibikase Therapeutics (Nasdaq: IKT) announced the FDA's clearance of its Investigational New Drug application for IkT-001Pro, aimed at treating Chronic Myelogenous Leukemia (CML). The SMP letter allows the initiation of a bioequivalence study to assess safety compared to imatinib, with preclinical data suggesting IkT-001Pro may be 3.4 times safer than imatinib. This prodrug formulation aims to enhance patient adherence and quality of life by reducing gastrointestinal side effects. Inhibikase's pipeline also includes treatments for Parkinson's and related disorders.
Inhibikase Therapeutics, Inc. (IKT) has announced the dosing of the first patient in its Phase 2a '201 trial' for IkT-148009, a c-Abl inhibitor aimed at treating Parkinson's disease. This trial involves 120 untreated patients and will evaluate safety, tolerability, and pharmacokinetics over 12 weeks. Preliminary animal studies suggested functional recovery could occur within eight weeks. The company anticipates increased patient enrollment as more trial sites become operational, highlighting its commitment to improving the lives of those affected by neurodegenerative diseases.
Inhibikase Therapeutics (Nasdaq: IKT) reported a net loss of $4.6 million, or $0.18 per share, for Q2 2022, compared to a net loss of $2.6 million, or $0.22 per share, in Q2 2021. R&D expenses increased by $0.6 million to $3.0 million, driven by clinical trial costs. The company has opened enrollment for its Phase 2a trial of IkT-148009 for Parkinson's disease and filed an IND application for IkT-001Pro for chronic myelogenous leukemia. As of June 30, 2022, Inhibikase had $32.2 million in cash, sufficient to fund operations through December 2023.
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced it will release its financial results for Q2 2022 on August 12, 2022. The company will follow up with a conference call on August 15, 2022, at 8:00 a.m. ET to discuss the results and provide a corporate update. Inhibikase specializes in developing therapeutics for Parkinson's disease and related disorders, focusing on its lead program, IkT-148009, a c-Abl inhibitor.
Inhibikase Therapeutics (Nasdaq: IKT) has announced the advancement of its Phase 2a study ('201 trial') for IkT-148009 after favorable results from the Phase 1/1b ('101 trial'). The 101 trial, which evaluated dosing in Parkinson's patients, demonstrated a positive safety and tolerability profile. The FDA has granted approval to proceed with the 201 trial, expecting to dose the first patient by 2Q 2022. The upcoming trial will focus on long-term safety and efficacy in untreated Parkinson’s patients, marking a significant step in addressing unmet needs in Parkinson's disease treatment.
Inhibikase Therapeutics (Nasdaq: IKT) reported its Q1 2022 financial results, revealing a net loss of $4.7 million, or $0.18 per share, up from a loss of $2.6 million, or $0.26 per share, in Q1 2021. R&D expenses rose to $3.0 million, primarily due to Phase I clinical trial expenditures. Cash and cash equivalents were $36.6 million, sufficient to fund operations into Q3 2023. The company anticipates initiating its Phase 2a study for IkT-148009 in Parkinson's disease and submitting an IND for IkT-001Pro for Chronic Myelogenous Leukemia this quarter.